

Bicycle

Bicycle Therapeutics to Present Posters at the SITC 35th Anniversary Annual Meeting

October 14, 2020

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Oct. 14, 2020-- [Bicycle Therapeutics plc](#) (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (*Bicycle*[®]) technology, today announced that preclinical data for BT7480, a tumor-targeted immune cell agonist (TICA[™]), and an EphA2/CD137 TICA will be presented during an e-poster session at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting on November 10-15, 2020.

BT7480 is a novel, fully synthetic TICA targeting Nectin-4, a well-validated tumor antigen, and agonizing CD137. EphA2/CD137 TICAs are comprised of *Bicycles* that target the tumor antigen EphA2, which is overexpressed in a range of solid tumor types and associated with poor outcomes, and *Bicycles* that agonize CD137.

Details on Bicycle's poster presentations at SITC are as follows:

Poster Title: BT7480, a fully synthetic tumor-targeted immune cell agonist (TICA[™]) induces tumor localized CD137 agonism and modulation of tumor immune microenvironment

Abstract #: 706

Session Date and Time: Wednesday, November 11, 2020 – Saturday, November 14, 2020; 9:00 a.m. – 5:00 p.m. ET

Poster Title: EphA2/CD137 *Bicycle* tumor-targeted immune cell agonists (TICAs[™]) induce tumor regressions, immunogenic memory, and reprogramming of the tumor immune microenvironment

Abstract #: 700

Session Date and Time: Wednesday, November 11, 2020 – Saturday, November 14, 2020; 9:00 a.m. – 5:00 p.m. ET

The posters will be available on the Publications section of bicycletherapeutics.com following presentation.

About Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as *Bicycles*[®], for diseases that are underserved by existing therapeutics. *Bicycles* are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making *Bicycles* attractive candidates for drug development. Bicycle's lead product candidate, BT1718, a *Bicycle* Toxin Conjugate (BTC) that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I/II study. BT8009 is a BTC targeting Nectin-4, a well-validated tumor antigen, and is also currently being evaluated a Company-sponsored Phase I/II trial. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20201014005994/en/): <https://www.businesswire.com/news/home/20201014005994/en/>

Investor and Media Contact:

Bicycle Therapeutics

Maren Killackey

maren.killackey@bicycletx.com

+1-617-203-8300

Source: Bicycle Therapeutics plc